Annualized rate of biologic or JAKi addition/switching, by MBDA test score utilization (n=3,953 eligible rheumatologists)

JAKi : Janus Kinase inhibitor; MBDA: Multi-biomarker disease activity; RA: Rheumatoid arthritis.

Rank 0 refers to physicians who did not order the MBDA test for any RA patient with fee-for-service Medicare in that year. Ranks 1–4 correspond to the first (lowest) to fourth (highest) quartiles of MBDA test utilization in the practices of clinicians who ordered the test at least once inthat year. Analysis was restricted to rheumatologists who cared for at least 10 RA patients in each pairwise year comparison.

The p-value for test for interaction between year and rank is 0.55.